Avelox approved for resistant pneumonia strains
Bayer Avelox (moxifloxacin) receives supplemental approval for the treatment of community acquired pneumonia caused by multi-drug resistant Streptococcus pneumoniae May 18. Avelox had been approved to treat mild to moderate community acquired pneumonia. The product is the first antibiotic available in both I.V. and tablets to treat those strains, the company said. Oscient Pharmaceuticals' Factive (gemifloxacin) and Aventis' Ketek (telithromycin), which are available in tablets, also have indications for the strains...
You may also be interested in...
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
No device-related close-out letters were released by the US FDA last month.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.